Coherus Oncology (CHRS) Non-cash Items (2014 - 2025)

Coherus Oncology has disclosed Non-cash Items across 12 years of filings, most recently posting $18.2 million for Q4 2025.

• Non-cash Items for Q4 2025 came in at $18.2 million, up 7.21% year-over-year; the trailing twelve-month figure through Dec 2025 was $18.2 million (up 7.21% YoY), and the FY2025 annual result was $18.2 million, up 7.21% from the prior year.
• Non-cash Items came in at $18.2 million for Q4 2025 at Coherus Oncology, up from $17.0 million in the prior quarter.
• In the past five years, Non-cash Items ranged from a high of $61.4 million in Q4 2021 to a low of $2.5 million in Q4 2022.
• The 5-year median for Non-cash Items is $18.2 million (2025), against an average of $27.3 million.
• Across the five-year window, Non-cash Items tumbled 95.88% in 2022 and surged 1377.84% in 2023, its largest moves.
• Coherus Oncology's Non-cash Items stood at $61.4 million in 2021, then sank by 95.88% to $2.5 million in 2022, then soared by 1377.84% to $37.4 million in 2023, then sank by 54.52% to $17.0 million in 2024, then climbed by 7.21% to $18.2 million in 2025.
• The last three Non-cash Items figures came in at $18.2 million (Q4 2025), $17.0 million (Q4 2024), and $37.4 million (Q4 2023), per Business Quant data.